Abstract: This invention relates to the preparation of N-(phosphonomethyl)glycine (“glyphosate”) from N-(phosphonomethyl)iminodiacetic acid (“PMIDA”), and more particularly to methods for control of the conversion of PMIDA, for the identification of reaction end points relating to PMIDA conversion and the preparation of glyphosate products having controlled PMIDA content.

Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.

Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.

Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.

Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.

Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding, treating or preventing bone degradation. In some embodiments, the agent for avoiding, treating or preventing bone degradation is zoledronic acid. In other embodiments, the agent is clodronate or denosumab.

Abstract: The present invention relates to the design of a customized therapy for a subject with breast cancer based on the c-MAF expression level and the menopausal status of the subject. In some embodiments, the customized therapy comprises an agent for avoiding or preventing bone degradation. In some embodiments, the agent for avoiding or preventing bone degradation is zoledronic acid.

Abstract: Processes using high temperature thermoplastic polymers in the in-situ fabrication in the formation of foamed composite sandwich or foam articles often result in weak unsound products which may be avoided by utilizing a high temperature thermoplastic in powder form (22), a blowing agent having a high decomposition temperature (24), and, if desired, reinforcers and/or fillers, (28), mixing the thermoplastic, blowing agent and reinforcer and fillers (30), placing the mixture in a mold and, if forming a composite structure, in abutment with at least one skin (34), and applying sufficient heat and/or pressure to the mold and its contents to melt the thermoplastic and generate gas within said mixture by decomposition of the blowing agent (38). Also, an activator may be included with the blowing agent which promotes the production of gas (26). The thermoplastic should be free from any material which will react with the blowing agent or the activator at temperatures below the melting point of the thermoplastic.

Abstract: A material spreader for spreading sand, salt or the like. The spreader is mounted on a vehicle or a trailer with the material being discharged from the rear. The spreader includes a fiberglass hopper and hopper housing with a stainless steel endless conveyor for reducing corrosion and wear. A spinner assembly, used for spreading the material, and the conveyor are driven by a variable speed engine. The engine controls the speed of the conveyor and spinner assembly independently of the speed of the vehicle.